Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab in Critically Ill COVID-19 Pneumonia (CD16)
NCT04901689Phase 3Suspended
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of leronlimab in COVID-19 pneumonia, sponsored by Hospital Israelita Albert Einstein. Started Oct 2021; status: suspended.
02
Drugs
leronlimab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04901689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901689.